中等度から重度の関節リウマチ患者を対象とした研究

基本情報

NCT ID

NCT01721057

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

684

治験依頼者名

Eli Lilly and Company

概要

The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily (QD) is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had inadequate response to or are intolerant to at least 1 conventional disease-modifying antirheumatic drug (cDMARD)(cDMARD-IR \[inadequate response\] participants) and who have not received a biologic disease-modifying antirheumatic drug (DMARD).

対象疾患

介入

依頼者（Sponsor）